KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Accounts Payables (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Accounts Payables for 18 consecutive years, with $1.0 billion as the latest value for Q1 2026.

  • For Q1 2026, Accounts Payables rose 45.58% year-over-year to $1.0 billion; the TTM value through Mar 2026 reached $1.0 billion, up 45.58%, while the annual FY2025 figure was $939.0 million, 18.94% up from the prior year.
  • Accounts Payables hit $1.0 billion in Q1 2026 for Regeneron Pharmaceuticals, up from $939.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.0 billion in Q1 2026 and bottomed at $470.3 million in Q1 2022.
  • Average Accounts Payables over 5 years is $661.1 million, with a median of $599.5 million recorded in 2023.
  • Year-over-year, Accounts Payables decreased 13.37% in 2022 and then soared 81.74% in 2025.
  • Regeneron Pharmaceuticals' Accounts Payables stood at $589.2 million in 2022, then grew by 2.95% to $606.6 million in 2023, then surged by 30.15% to $789.5 million in 2024, then grew by 18.94% to $939.0 million in 2025, then grew by 9.38% to $1.0 billion in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $1.0 billion, $939.0 million, and $903.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.